Email this article Patient noncompliance as the cause of skin toxicity in capecitabine therapy
- Authors: Kogoniya L.M.1,2, Borisov K.E.2, Ershova K.I.2
-
Affiliations:
- M.F. Vladimirsky Moscow Region Scientific Research Clinical Institute
- “Clinic K+31” JSC
- Issue: Vol 2, No 3 (2022)
- Pages: 55-58
- Section: RARE COMPLICATIONS, QUALITY OF LIFE, AND FOLLOW-UP CARE OF ONCOHEMATOLOGICAL PATIENTS
- Published: 13.10.2022
- URL: https://mdonco.abvpress.ru/jour/article/view/46
- DOI: https://doi.org/10.17650/2782-3202-2022-2-3-55-58
- ID: 46
Cite item
Full Text
Abstract
When using capecitabine, manifestations of toxicity in the form of palmar-plantar dysesthesia, redness, excessive sensitivity and peeling of the skin of the palms and feet are well known. However, in the scientific literature available to us, we did not find a single case of skin toxicity with capecitabine, in contrast to targeted therapy, for which skin manifestations are very characteristic. The dermal toxicity described in this paper developed as a result of patient noncompliance. These side effects reduced the adherence to therapy: the next courses of chemotherapy were postponed.
About the authors
L. M. Kogoniya
M.F. Vladimirsky Moscow Region Scientific Research Clinical Institute;“Clinic K+31” JSC
Author for correspondence.
Email: Lali51@yandex.ru
ORCID iD: 0000-0003-3326-4961
Lali M. Kogoniya
61/2 Shchepkina St., Moscow 129110,
Bld. 4, 42 Lobachevskogo St., Moscow 119415
Russian Federation
K. E. Borisov
“Clinic K+31” JSC
ORCID iD: 0000-0002-8003-9401
Bld. 4, 42 Lobachevskogo St., Moscow 119415
Russian FederationK. I. Ershova
“Clinic K+31” JSC
ORCID iD: 0000-0002-4289-0748
Bld. 4, 42 Lobachevskogo St., Moscow 119415
Russian FederationReferences
- Khobeysh M.M., Monakhov K.N. Daivobet – a newer highly effective preparation for external treatment of psoriasis of the palms and the soles. Klinicheskaya dermatologiya i venerologiya = Russian journal of clinical dermatology and venerology 2008;6(1):41–5. Available at: https://medi.ru/info/5518.
- Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6(10):803–12. doi: 10.1038/nrc1970
- Pomerantz G., Mirvish E.D., Geskin L.J. Cutaneous reactions to epidermal growth factor inhibitors. J Drugs Dermatol 2010;9(10):1229–34.
- Common Terminology Criteria for Adverse Events. Version 4.03. US Department of Health and Human Services, National Institutes of Health, NCI, Bethesda, MD, 2010. Available at: http://evs.nci.nih.gov/ftpl/CTCAE.4.03.2010-06-14.
- Dy G.K., Adjei A.A. Understanding, recognizing and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013;63(4):249–79. doi: 10.3322/caac.21184
- Kogoniya L.M., Mazurin V.S., Ilnitskaya O.V. et al. Palmar-and-plantar erythrodysesthesia is a series complications after capecitabin: our own experience. Almanah klinicheskoy meditsiny = Almanac of Clinical Medicine 2013;28:37–40.
- Nagore E., Insa A., Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (’hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000;1(4):225–34.
- Dikaya L.A. Communicative competence of clinical psychologist. A study guide. Rostov-on-Don: Izdatelstvo Yuzhnogo federalnogo universiteta, 2016. 108 p. Available at: https://znanium.com/catalog/product/991896.
Supplementary files
